Pacific Edge Ltd banner

Pacific Edge Ltd
NZX:PEB

Watchlist Manager
Pacific Edge Ltd Logo
Pacific Edge Ltd
NZX:PEB
Watchlist
Price: 0.24 NZD 4.35% Market Closed
Market Cap: NZ$245.4m

Relative Value

The Relative Value of one PEB stock under the Base Case scenario is hidden NZD. Compared to the current market price of 0.24 NZD, Pacific Edge Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PEB Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

PEB Competitors Multiples
Pacific Edge Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
Pacific Edge Ltd
NZX:PEB
235.1m NZD 14.6 -7.1 -6.2 -6.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
405B USD 6.8 172.2 16.6 23.6
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD 462 374.5 -2 631.9 -2 377 -2 377
US
Amgen Inc
NASDAQ:AMGN
204.8B USD 5.6 26.6 15.2 15.2
US
Gilead Sciences Inc
NASDAQ:GILD
186B USD 6.3 21.9 14.8 14.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.3B USD 10.3 31.2 23.9 24.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83B USD 5.8 18.5 14.1 16
NL
argenx SE
XBRU:ARGX
43B EUR 14.2 33.5 57.5 59
AU
CSL Ltd
ASX:CSL
71.4B AUD 3.2 16.5 11.4 14.2
P/S Multiple
Revenue Growth P/S to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average P/S: 3 100 708.6
14.6
20%
0.7
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
10%
0.7
US
Astria Therapeutics Inc
NASDAQ:ATXS
462 374.5
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.6
3%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
6.3
5%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
11%
0.9
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
10%
0.6
NL
argenx SE
XBRU:ARGX
14.2
49%
0.3
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
P/E Multiple
Earnings Growth PEG
NZ
Pacific Edge Ltd
NZX:PEB
Average P/E: 45.8
Negative Multiple: -7.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.2
89%
1.9
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 631.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.6
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.9
14%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
17%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
NL
argenx SE
XBRU:ARGX
33.5
42%
0.8
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average EV/EBITDA: 21.9
Negative Multiple: -6.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 377 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.2
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
18%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
15%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
23%
0.6
NL
argenx SE
XBRU:ARGX
57.5
810%
0.1
AU
CSL Ltd
ASX:CSL
11.4
8%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average EV/EBIT: 24
Negative Multiple: -6.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 377 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.2
2%
7.6
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
21%
0.8
NL
argenx SE
XBRU:ARGX
59
N/A N/A
AU
CSL Ltd
ASX:CSL
14.2
11%
1.3